Y-mAbs Therapeutics Inc YMAB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/07/24 EDT
17.21UNCH (UNCH)
Volume
2,907
Close
17.21UNCH (UNCH)
Volume
383,645
52 week range
4.60 - 20.90
Loading...
  • Open17.24
  • Day High17.47
  • Day Low16.98
  • Prev Close17.21
  • 52 Week High20.90
  • 52 Week High Date03/01/24
  • 52 Week Low4.60
  • 52 Week Low Date08/14/23

Key Stats

  • Market Cap755.048M
  • Shares Out43.87M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.75
  • YTD % Change152.35

KEY STATS

  • Open17.24
  • Day High17.47
  • Day Low16.98
  • Prev Close17.21
  • 52 Week High20.90
  • 52 Week High Date03/01/24
  • 52 Week Low4.60
  • 52 Week Low Date08/14/23
  • Market Cap755.048M
  • Shares Out43.87M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.75
  • YTD % Change152.35

RATIOS/PROFITABILITY

  • EPS (TTM)-0.49
  • P/E (TTM)-35.06
  • Fwd P/E (NTM)-34.91
  • EBITDA (TTM)-20.455M
  • ROE (TTM)-20.39%
  • Revenue (TTM)84.819M
  • Gross Margin (TTM)86.60%
  • Net Margin (TTM)-25.26%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/07/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Y-mAbs Therapeutics Inc

 

Profile

MORE
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug...
Thomas Gad
Vice Chairman of the Board, Chief Business Officer
James Healy M.D., Ph.D.
Independent Chairman of the Board
Michael Rossi
President, Chief Executive Officer, Director
Joris Wilms
Chief Operating Officer, Senior Vice President
Bo Kruse
Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Address
230 PARK AVENUE, SUITE 3350
New York, NY
10169
United States

Top Peers

SYMBOLLASTCHG%CHG
NRIX
Nurix Therapeutics Inc
14.16UNCHUNCH
RGNX
Regenxbio Inc
16.96UNCHUNCH
SAGE
SAGE Therapeutics Inc
12.98UNCHUNCH
CVAC
CureVac NV
2.99UNCHUNCH
URGN
Urogen Pharma Ltd
13.45UNCHUNCH